ILMN has been the subject of several other reports. Credit Suisse Group reaffirmed a “buy” rating and issued a $340.00 price objective on shares of Illumina in a research report on Wednesday, July 31st. Deutsche Bank reduced their price target on shares of Illumina from $290.00 to $280.00 and set a “hold” rating for the company in a research report on Friday, July 12th. ValuEngine raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Wolfe Research initiated coverage on shares of Illumina in a research report on Thursday, May 30th. They set an “outperform” rating for the company. Finally, Argus reduced their price target on shares of Illumina to $340.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $330.92.
Shares of Illumina stock opened at $290.50 on Tuesday. The firm has a market capitalization of $42.07 billion, a P/E ratio of 50.79, a PEG ratio of 2.67 and a beta of 1.10. The company has a quick ratio of 6.10, a current ratio of 6.79 and a debt-to-equity ratio of 0.42. The company has a 50 day moving average price of $310.31 and a 200 day moving average price of $315.12. Illumina has a 52 week low of $268.62 and a 52 week high of $380.76.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.03. The firm had revenue of $838.00 million during the quarter, compared to analyst estimates of $835.12 million. Illumina had a net margin of 27.56% and a return on equity of 21.73%. Illumina’s revenue was up 1.0% on a year-over-year basis. During the same period last year, the firm posted $1.43 EPS. As a group, research analysts anticipate that Illumina will post 6.04 earnings per share for the current fiscal year.
In other Illumina news, insider Francis A. Desouza sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $309.69, for a total value of $929,070.00. Following the completion of the sale, the insider now owns 70,536 shares in the company, valued at $21,844,293.84. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Mostafa Ronaghi sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $285.52, for a total value of $2,855,200.00. Following the sale, the senior vice president now owns 86,585 shares of the company’s stock, valued at approximately $24,721,749.20. The disclosure for this sale can be found here. Insiders sold 60,458 shares of company stock valued at $19,329,754 over the last ninety days. 0.38% of the stock is currently owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the company. Next Capital Management LLC purchased a new position in Illumina in the second quarter worth $25,000. Strategy Asset Managers LLC purchased a new position in Illumina in the first quarter worth $26,000. C J Advisory Inc purchased a new position in Illumina in the first quarter worth $29,000. Mizuho Securities Co. Ltd. acquired a new stake in Illumina in the first quarter valued at $37,000. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Illumina in the second quarter valued at $37,000. Institutional investors and hedge funds own 92.09% of the company’s stock.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: What are the advantages to having securities held in street name?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.